Actively Recruiting
Impact of Post-ARDS Covid-19 Sedation on Persistent Neuroinflammation
Led by Assistance Publique - Hôpitaux de Paris · Updated on 2024-12-24
72
Participants Needed
1
Research Sites
202 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
ICU Patients admitted after ARDS due to COVID infection should be weaned from invasive mechanical ventilation as quickly as possible. 60% of ARDS patient after COVID infection admitted in ICU developp a delirium during mechanical ventilation weaning, serious event that can lead to death or acute and late complications since 30% of patients who had a delirium in ICU develop cognitive sequelae. Based on epidemiological arguments and mouse models, severe neuroinflammation is considered to be one of the physiopathological mechanisms causing delirium during ventilatory weaning. In addition to its sedative properties, dexmedetomidine exhibits neuroprotective effects. In experimental models, dexmedetomidine reduces brain inflammation acting directly on the microglial phenotype. The role of this chronic neuroinflammatory condition on cognitive abilities and reserve begins to emerge in the literature no matter the initial stress is (surgery, head trauma, or Alzheimer's type dementia) and is therefore able to influence quality of life. The evaluation of this neuroinflammation by non-invasive tools appears essential in the management and follow-up of post-COVID cerebrolesed patients, as well as the potentially neuroprotective evaluation of dexmedetomidine.
CONDITIONS
Official Title
Impact of Post-ARDS Covid-19 Sedation on Persistent Neuroinflammation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patient aged 18 to 74 years at the time of inclusion
- Confirmed COVID-19 infection by PCR test from nasopharyngeal or bronchoalveolar sample
- High or intermediate affinity TPSO genotype for [18F]-DPA-714
- Hospitalized in intensive care for ARDS after COVID-19 requiring mechanical ventilation and deep sedation for at least 24 hours
- Alive at 24 months (+ 24 months) after intensive care discharge
- Signed informed consent
- Affiliated to a National French social security system (excluding French State Medical Aid)
- For dexmedetomidine group: received dexmedetomidine for at least 24 hours during ICU stay
- For non-dexmedetomidine group: did not receive dexmedetomidine during ICU stay
You will not qualify if you...
- Under legal protection, guardianship, or curatorship
- Pregnant or breastfeeding
- Contraindication to PET or MRI examination
- Severe kidney impairment (creatinine clearance less than 30 mL/min)
- Contraindication to the radiopharmaceutical agent [18F]-DPA-714
- Serious neurological history at ICU admission including stroke, severe head trauma, or dementia with loss of autonomy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Anesthesy department - Hôpital Pitié Salpêtrière
Paris, France, 75013
Actively Recruiting
Research Team
V
Vincent DEGOS, Pr
CONTACT
L
Laurence JALIN, Dr
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here